Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 3, 2025 · Filed Jun 5, 2025
Teva Pharmaceutical Industries's Global Operations sold $106K of Teva Pharmaceutical Industries shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$105,628
Shares × reported transaction price
27 days after results of May 7, 2025, 57 days before results of Jul 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Eliyahu Sharon Kalif (EVP, Chief Financial Officer) sold ~$952K of Teva Pharmaceutical Industries
Planned saleInsider selling
Traded May 8, 2025 · filed 4 days laterNot reported under a pre-arranged trading plan
Teva Pharmaceutical Industries's See "Remarks" sold $6.1M of Teva Pharmaceutical Industries shares. The filing does not indicate a pre-arranged trading plan.
Richard Daniell (Exec. VP, European Commercial) sold ~$359K of Teva Pharmaceutical Industries
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
